阿托伐他汀短期干预对急性冠脉综合征患者血浆OX40L及hsCRP的影响  

Effects of short term atorvastatin intervene on plasma OX40L and high sensitivity C-reactive protein in patients with acute coronary syndrome

作　　者：胡雪松[1] 黄志超[1] 许香广[1] 张新霞[1] 张国良[1] 

机构地区：[1]广东医学院附属深圳市福田人民医院心内科,广东深圳518033

出　　处：《岭南心血管病杂志》2009年第5期366-369,共4页South China Journal of Cardiovascular Diseases

摘　　要：目的探讨阿托伐他汀早期应用对急性冠脉综合征(acute coronary syndrome,ACS)患者血浆OX40L及高敏C反应蛋白(high sensitivety C-reactive protein,hsCRP)的影响。方法选取30例ACS患者为实验组,以20例非冠状动脉性心脏病(冠心病)患者作为对照组,采用酶联免疫吸附法测定实验组和对照组入院次日清晨、实验组服用阿托伐他汀(20mg/d)治疗7d后血浆OX40L和hsCRP的浓度,并进行统计学分析。结果ACS患者血浆OX40L、hsCRP浓度高于对照组,差异有统计学意义[(32.79±20.67)pg/mLvs.(12.95±5.46)pg/mL,P<0.01;(19.70±5.50)μg/mLvs.(1.29±0.59)μg/mL,P<0.01],且ACS患者血浆OX40L浓度和hsCRP浓度之间呈正相关(r=0.553,P=0.0001);经阿托伐他汀治疗7d后,ACS患者血浆OX40L、hsCRP浓度较治疗前显著降低,差异有统计学意义[(17.28±8.00)pg/mLvs.(32.79±20.67)pg/mL,P<0.01;(8.61±2.05)μg/mLvs.(19.70±5.50)μg/mL,P<0.01]。结论阿托伐他汀在ACS早期使用可降低血浆OX40L、hsCRP浓度,从而降低斑块内的炎症反应,改善斑块稳定性。Objectives To investigate the changes of plasma OX40 ligand ( OX40L) and high sensitivety C-reactive protein ( hsCRP) concentration in the patients with acute coronary syndrome ( ACS) before and after the short term atorvastatin intervene. Methods Treatment group included 30 patients (19 males, 11 females, 32-87 years) with ACS received 20 mg atorvastatin nightly for 7 days. Control group included 20 healthy subjects (10 males, 10 females, 41 -78 years). Plasma concentration of OX40L and hsCRP were measured by enzyme-linked immunosorbent assay ( ELISA). Results The plasma concentration of OX40L and hsCRP in ACS patients were significantly higher than control group [(32.79±20.67) pg/mL vs. (12.95±5.46) pg/mL, P<0.01; (19.70±5.50) μg / mL vs. ( 1.29 ±0.59) μg / mL, P <0.01]. And there was a positive correlation between OX40L and hsCRP in ACS patients ( r =0.553, P =0.000). The concentration of OX40L and hsCRP after the atorvastatin intervene were significantly decreased [(17.28±8.00) pg / mL vs. (32.79±20.67) pg / mL, P<0.01; (8.61±2.05) μg / mL vs. ( 19.70 ±5.50) μg / mL, P <0.01]. Conclusions The plasma concentration of OX40L and hsCRP decreased ofter short term atorvastatin treatment, which indicated that atorvastation may decrease the level of inflammation and improve the stability of vulnerable plaque in the patients with ACS.

关 键 词：冠状动脉疾病 C反应蛋白 OX40L 他汀 炎症 

分 类 号：R543.3[医药卫生—心血管疾病]